Literature DB >> 35313030

Hepatic kinome atlas: An in-depth identification of kinase pathways in liver fibrosis of humans and rodents.

Justin F Creeden1, Zachary A Kipp2, Mei Xu2, Robert M Flight3,4,5, Hunter N B Moseley3,4,5,6,7, Genesee J Martinez2, Wang-Hsin Lee2, Khaled Alganem1, Ali S Imami1, Megan R McMullen8, Sanjoy Roychowdhury8, Atta M Nawabi9, Jennifer A Hipp10, Samir Softic2,11, Steven A Weinman12, Robert McCullumsmith1,13, Laura E Nagy8,14,15, Terry D Hinds2,4,16.   

Abstract

BACKGROUND AND AIMS: Resolution of pathways that converge to induce deleterious effects in hepatic diseases, such as in the later stages, have potential antifibrotic effects that may improve outcomes. We aimed to explore whether humans and rodents display similar fibrotic signaling networks. APPROACH AND
RESULTS: We assiduously mapped kinase pathways using 340 substrate targets, upstream bioinformatic analysis of kinase pathways, and over 2000 random sampling iterations using the PamGene PamStation kinome microarray chip technology. Using this technology, we characterized a large number of kinases with altered activity in liver fibrosis of both species. Gene expression and immunostaining analyses validated many of these kinases as bona fide signaling events. Surprisingly, the insulin receptor emerged as a considerable protein tyrosine kinase that is hyperactive in fibrotic liver disease in humans and rodents. Discoidin domain receptor tyrosine kinase, activated by collagen that increases during fibrosis, was another hyperactive protein tyrosine kinase in humans and rodents with fibrosis. The serine/threonine kinases found to be the most active in fibrosis were dystrophy type 1 protein kinase and members of the protein kinase family of kinases. We compared the fibrotic events over four models: humans with cirrhosis and three murine models with differing levels of fibrosis, including two models of fatty liver disease with emerging fibrosis. The data demonstrate a high concordance between human and rodent hepatic kinome signaling that focalizes, as shown by our network analysis of detrimental pathways.
CONCLUSIONS: Our findings establish a comprehensive kinase atlas for liver fibrosis, which identifies analogous signaling events conserved among humans and rodents.
© 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35313030      PMCID: PMC9489820          DOI: 10.1002/hep.32467

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.298


  29 in total

Review 1.  Biliverdin reductase isozymes in metabolism.

Authors:  Luke O'Brien; Peter A Hosick; Kezia John; David E Stec; Terry D Hinds
Journal:  Trends Endocrinol Metab       Date:  2015-02-25       Impact factor: 12.015

Review 2.  Liver fibrosis: Direct antifibrotic agents and targeted therapies.

Authors:  Detlef Schuppan; Muhammad Ashfaq-Khan; Ai Ting Yang; Yong Ook Kim
Journal:  Matrix Biol       Date:  2018-04-12       Impact factor: 11.583

3.  Hepatic fibrosis is enhanced and accompanied by robust oval cell activation after chronic carbon tetrachloride administration to Egr-1-deficient mice.

Authors:  Michele T Pritchard; Laura E Nagy
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

4.  Yu Gan Long Ameliorates Hepatic Fibrosis by Inhibiting PI3K/AKT, Ras/ERK and JAK1/STAT3 Signaling Pathways in CCl4-induced Liver Fibrosis Rats.

Authors:  Hou-Gang Li; Peng-Tao You; Yu Xia; Yu Cai; Yi-Jun Tu; Meng-Heng Wang; Wan-Ci Song; Tai-Min Quan; Hui-Ying Ren; Yan-Wen Liu; Han-Xiong Dan; Shi-Qing Xu
Journal:  Curr Med Sci       Date:  2020-07-17

Review 5.  Biliverdin reductase and bilirubin in hepatic disease.

Authors:  Lauren Weaver; Abdul-Rizaq Hamoud; David E Stec; Terry D Hinds
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-01       Impact factor: 4.052

6.  Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation.

Authors:  G Carpino; S Morini; S Ginanni Corradini; A Franchitto; M Merli; M Siciliano; F Gentili; A Onetti Muda; P Berloco; M Rossi; A F Attili; E Gaudio
Journal:  Dig Liver Dis       Date:  2005-05       Impact factor: 4.088

7.  Glucocorticoid receptor β stimulates Akt1 growth pathway by attenuation of PTEN.

Authors:  Lance A Stechschulte; Leah Wuescher; Joseph S Marino; Jennifer W Hill; Charis Eng; Terry D Hinds
Journal:  J Biol Chem       Date:  2014-05-09       Impact factor: 5.157

8.  Non-Alcoholic Steatohepatitis in Myotonic Dystrophy: DMPK Gene Mutation, Insulin Resistance and Development of Steatohepatitis.

Authors:  Rishi R Bhardwaj; Andrea Duchini
Journal:  Case Rep Gastroenterol       Date:  2010-03-17

9.  Insulin resistance in liver cirrhosis: decreased insulin binding to circulating monocytes.

Authors:  A V Greco; A Bertoli; G Ghirlanda; R Manna; L Altomonte; A G Rebuzzi
Journal:  Horm Metab Res       Date:  1980-11       Impact factor: 2.936

10.  Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways.

Authors:  G Svegliati-Baroni; F Ridolfi; A Di Sario; A Casini; L Marucci; G Gaggiotti; P Orlandoni; G Macarri; L Perego; A Benedetti; F Folli
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

View more
  3 in total

1.  Ovarian Hormones Regulate Nicotine Consumption and Accumbens Glutamatergic Plasticity in Female Rats.

Authors:  Erin E Maher; Zachary A Kipp; Jonna M Leyrer-Jackson; Shailesh Khatri; Emma Bondy; Genesee J Martinez; Joshua S Beckmann; Terry D Hinds; Heather A Bimonte-Nelson; Cassandra D Gipson
Journal:  eNeuro       Date:  2022-06-27

2.  Antioxidant Therapy Significantly Attenuates Hepatotoxicity following Low Dose Exposure to Microcystin-LR in a Murine Model of Diet-Induced Non-Alcoholic Fatty Liver Disease.

Authors:  Apurva Lad; Jonathan Hunyadi; Jacob Connolly; Joshua D Breidenbach; Fatimah K Khalaf; Prabhatchandra Dube; Shungang Zhang; Andrew L Kleinhenz; David Baliu-Rodriguez; Dragan Isailovic; Terry D Hinds; Cara Gatto-Weis; Lauren M Stanoszek; Thomas M Blomquist; Deepak Malhotra; Steven T Haller; David J Kennedy
Journal:  Antioxidants (Basel)       Date:  2022-08-22

Review 3.  Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.

Authors:  Olufunto O Badmus; Sarah A Hillhouse; Christopher D Anderson; Terry D Hinds; David E Stec
Journal:  Clin Sci (Lond)       Date:  2022-09-30       Impact factor: 6.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.